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Introduction 
Sepsis has traditionally been defined as a systemic 
inflammatory reaction of the organism to gram-
negative bacterial leading to septic shock and even-
tually to (septic) multi-organ failure. Interestingly, 
it has become evident that the final common 
pathways of multi-organ failure initiated by trauma 
or by infection are very similar involving basically 
the same humoral and cell-dependent effectors and 
mediators. Amongst these, proteolytic enzyme 
systems have been suggested to play an equally im-
portant role in the course of sepsis-like syndrome 
and trauma-induced inflammatory response. As 
outlined in the chapter by Jochum et al. 
(pp 46-60), the lysosomal serine proteinase elas-
tase and the cysteine proteinases cathepsins B and 
L of the primary inflammatory cells, polymorpho-
nuclear (PMN) granulocytes and monocytes/ 
macrophages, respectively, are thought to be par-
ticularly potent effectors of proteolytic tissue 
damage i f they are discharged extracellularly in 
high amounts during activation and disintegration 
of the phagocytes due to multiple trauma or sepsis. 
The initial mechanisms of stimulation in these in-
flammatory processes, however, are significantly 
different. Bacterial endotoxin and other bacterial 
products, e.g., exotoxins, N-formylated peptides, 
and bacterial proteinases but also antigen-antibody 
complexes have been identified as potent stimula-
tors of the inflammatory response to infection. 
Although in more recent studies, gram-negative 
bacteria have not been recognized as the etiologic 
agent in more than half of the patients presenting 
symptoms of sepsis-like syndrome (Glauser et al. 
1991), the effects of bacterial endotoxin, a 
lipopolysaccharide (LPS) from the cell wall of 
gram-negative bacteria, have been characterized in 
detail in numerous studies. Endotoxin administra-
tion to human volunteers activated most of the rele-
vant humoral and cellular cascade systems and pro-
duced cardiovascular changes that were qualitative-
ly similar to those seen in septic shock (Parrillo et 
al. 1990). Though endotoxin is able to produce sep-
532 M. Jochum et al. 
tic shock, it seems to be only one of several bacteri-
al products that can initiate or enhance the septic 
response. However, as a well-defined substance, 
bacterial LPS has become a valuable tool in various 
animal models of septic shock, one of which wil l be 
discussed in this chapter. 
Due to species differences in the inflammatory 
response, results obtained in animal experiments 
are only partially valid for the sepsis-like syndrome 
of patients. Considerable differences between 
animal models and human septic shock have been 
revealed with respect to proteolytic enzymes and 
their endogenous inhibitors. Thus, the most rele-
vant data on the role of proteinases, especially con-
cerning P M N elastase and cathepsin B, in human 
sepsis have been obtained from clinical studies, as 
reviewed below. In addition, preliminary results wil l 
be discussed on the effect of proteinase inhibitor 
substitution in septic patients. The local response 
observed in patients with diffuse peritonitis provid-
ed us with further insight into the proteolytic 
pathomechanisms of inflammation and their possi-
ble modulation by proteinase inhibition during sep-
sis-like multiple organ failure. 
Methods 
Serially drawn citrated plasma ( 2 - 4 specimens per 
day) and peritonitis exudate samples were used to 
quantify proteinases, inhibitors, and other proteins 
and their split products. The biochemical methods 
applied are outlined in detail in the chapter by 
Jochum et al. (pp 46-60). 
Clinical methods, criteria for grading the severi-
ty of the infectious disease and organ failure, treat-
ment of patients, and the protocol of the ex-
perimental therapeutic studies are extensively de-
scribed in the original publications cited in the 
following sections. 
Polymorphonuclear Granulocyte Elastase 
and Macrophage-Derived Cathepsin B 
Release in the Septic Course 
Plasma Levels of the Phagocyte Proteinases 
in Relation to the Severity of the Disease 
and the Consumption of Clotting Proteinases 
and Antithrombin III 
In several prospective clinical studies on more than 
200 patients suffering from bacterial infections 
after major surgery, we could demonstrate an in-
creasing release to P M N elastase into the circula-
tion in accordance with the worsening of the in-
flammatory reaction (Fig. 1 a) (Duswald et al. 1985; 
Inthorn and Jochum 1988; Jochum 1988; Jochum 
et al. 1990). Patients without postoperative infec-
tions showed only moderate transiently elevated 
plasma levels of complexed elastase (up to three 
times that of normal) after operation, whereas 
onset and course of sepsis were characterized by 
markedly increased concentrations up to 30-fold in 
individual patients. As a mean, in patients with 
persisting septicemia the elastase plasma levels re-
mained significantly elevated until death, while a 
recovery phase was accompanied by an obvious 
return to normal values. A detailed evaluation of 
our data (Jochum 1988; Inthorn and Jochum 1988) 
showed that in eventually dying patients a signifi-
cant increase of complexed elastase occurred 2 - 3 
days before clinical manifestation of severe sepsis, 
followed by a transient decrease and an additional-
ly significant rise, when sepsis was clinically 
diagnosed (Fig. 2). In surviving patients, however, 
the tremendous increase of P M N elastase in plasma 
did coincide with the clinical manifestation of the 
severe infection, whereas the recovery phase was 
clearly indicated earlier by declining elastase levels 
compared to the clinical assessment (Fig. 2). Thus, 
measuring P M N elastase in closely matched con-
secutive plasma samples (taken every 6 h) of severe-
ly i l l patients did not only allow an early diagnosis 
of the clinical state, but also suggests an involve-
ment of the granulocytic proteinase in the develop-
ment of severe infection and sepsis. 
In addition, we could demonstrate for the first 
time, in some pilot studies, that especially during a 
lethal septic course the monocyte/macrophage-de-
rived cathepsin B was released in a manner similar 
to the P M N elastase, suggesting that discharge of 
lysosomal cysteine proteinases may intensify the ex-
tracellular proteolytic capacity (Fig. 3). 
When complexed elastase and cathepsin B in-
creased in plasma, a prominent reduction of the 
humoral blood cascade proenzymes prekallikrein 
(Fig. 1 b) and prothrombin (Fig. 1 c) and of anti-
thrombin I I I (AT I I I ) inhibitory activity (Fig. 3 b) 
was measurable. This indicates that the proteolytic 
mechanisms in this pathological situation are quite 
similar to those seen in the course of developing 
posttraumatic organ failure (see the chapter by 
Jochum et al., pp46-60) . Results confirming our 
findings with respect to the release of PMN elastase 
and the consumption of hemostatic proteins in 
more than 150 patients developing infection and 
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Fig. 1. Plasma levels (mean±SEM) of a PMN elastase 
(in complex with arproteinase inhibitor), b kallikrein, 
and c prothrombin, according to the severity of post-
operative inflammation: group /, without postoperative 
complications; group II, wound infection and limited 
peritonitis; group III, widespread soft-tissue inflamma-
tion and peritonitis > 1 quadrant; group IV, clinically 
ensured sepsis; U = unit/ml; 1 U = normal plasma 
value; number in parentheses, number of single deter-
minations in each group 
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sepsis have been extensively published by Egbring's 
group (see reviews by Egbring et al. 1986 and Seitz 
et al. 1987). The authors found not only signifi-
cantly elevated elastase levels in septic patients but 
also in subjects with cardiac shock and fulminant 
hepatic failure. Yet, the highest values (up to 50-
fold that of normal) were measured in septic shock 
patients. 
In addition, Pacher et al. (1989) reported on a 
study with daily measurements of complexed plas-
ma elastase in a heterogeneous patient collective 
which could be divided into 32 septic and 24 un-
complicated postoperative and nonpostoperative 
patients. A significant difference in elastase plasma 
levels was seen between septic nonsurvivors and 
nonseptic patients, whereas septic survivors showed 
high levels equal to those of nonseptic postopera-
tive patients. Moreover, septic pulmonary insuffi-
ciency could be predicted 1 day before the need for 
mechanical ventilation by elastase levels above 
4-fold that of normal with a specificity of 80% and 
a sensitivity of 81%. With an even higher specifici-
ty (83%) and sensitivity (88%) this threshold level 
predicted multiple organ failure (MOF) 1 day 
before a MOF score of > 5 was evaluated. These 
results can be taken as a further hint of the patho-
genic potency of P M N elastase in the development 
of sepsis and MOF regardless of the inciting cause. 
The predictive validity of P M N elastase plasma 
levels for a forthcoming postoperative infection 
534 M. Jochum et al. 
Elastase 
ng/m! (xiSEM) 
Fig. 2. Plasma levels of PMN elastase (in complex with 
a!-proteinase inhibitor) in patients developing severe 
infection/sepsis. Days 1 to 4: clinical course with 
minor or without complications; days 5 to 9: clinically 
diagnosed life-threatening infection/sepsis; dotted line, 
nonsurvivors (n = 11); solid line, survivors (n = 11) 
— Cathepsin B —+— Elastase 
10 days 15 2 0 
A T I I I (activity) 
Fig. 3. a Cathepsin B activity and PMN 
elastase (in complex with aproteinase in-
hibitor) in plasma of a patient with lethal 
sepsis, expressed in multiples of normal, 
b Antithrombin I I I inhibitory activity in 
plasma of the same patient, expressed as 
°7o of normal 
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risk was also confirmed by Fink et al. (1989). In 12 
of 25 patients with colon-related surgical opera-
tions the complexed elastase in plasma was still sig-
nificantly elevated above normal on the 5th post-
operative day, thereby indicating a forthcoming in-
fection at least 3 days before the clinical verifica-
tion of the complication on day 8-10. In un-
complicated cases a steady decrease after the opera-
tion-induced elevation was noticed. In another 
study of this research group (Fink et al. 1988), in-
volving 56 intensive care patients undergoing ab-
dominal surgery, the operation procedure induced 
a 3-fold increase of elastase plasma levels in 31 pa-
tients with an uncomplicated postoperative course, 
whereas in patients with an early postoperative sep-
sis a more than 5-fold elevation above normal was 
measured. Ten patients who survived the septic 
episode where characterized by a steady decrease of 
complexed elastase and could not be differentiated 
from those without sepsis from the 48th post-
operative hour onwards. Septic nonsurvivors 
(n = 15), however, showed constantly high or even 
additionally increasing postoperative elastase 
levels. Thus, the authors concluded that a long 
lasting elevation of P M N elastase is highly in-
dicative of a serious deterioration of the septic 
situation. 
Just recently, Tanaka et al. (1991) compared dai-
ly measured elastase plasma levels of 16 patients 
with septic shock complicated by MOF with those 
of 30 patients with hemorrhagic shock secondary 
to severe injury over a period of 1 week. Whereas 
in the septic patients the shock period lasted for 
more than 7 days, patients suffering from severe in-
jury recovered from hemorrhagic shock within 
24 h. At diagnosis of septic shock complexed 
elastase was elevated up to a mean plasma level of 
8-fold that of normal and remained high during the 
ensuing week. In hemorrhagic shock the levels were 
also raised up to about 6-fold but quickly returned 
to normal at recovery. In this study the increase in 
complexed elastase in plasma was significantly cor-
related with decreases of plasmatic fibronectin and 
factor X I I I , two proteins known to be easily 
susceptible to proteolytic cleavage by P M N elastase 
(reviewed by Jochum 1988). Significant correlation 
was also found between elastase activity in bron-
choalveolar lavage fluid (BALF) samples and the 
respiratory index of the septic shock patients, thus 
suggesting that at least local tissue damage in sepsis 
and MOF may be in part due to the destructive 
potency of P M N elastase. 
Likewise, a highly significant positive correla-
tion between the plasma levels of complexed elas-
tase and the respiratory index was reported by Shi-
manuki et al. (1989) in 49 patients who underwent 
operations of various degrees of surgical stress. As 
the operative intervention became more severe, the 
plasma levels of granulocytic elastase rose. More-
over, marked and prolonged elevation of these plas-
ma levels paralleled postoperative pulmonary com-
plications. Patients with panperitonitis already 
showed mean complex plasma levels of more than 
7-fold over normal before operation, whereas in 
noninfectious underlying diseases only slightly 
elevated preoperative elastase levels were measured. 
Coinciding with our findings (Duswald et al. 1985) 
the elastase complex levels in patients with panperi-
tonitis did not increase after surgery but slightly de-
creased over time, probably due to the removal of 
the abdominal inflammatory focus enabling a con-
tinuous amelioration of the infection. 
Schöffel et al. (1989 a) studied a collective of 21 
patients undergoing major abdominal surgery in 
whom sepsis was diagnosed during their postopera-
tive stay on the ICU. A persistent elevation of com-
plexed elastase above 4-fold that of normal plasma 
values beyond the third postoperative day or an ad-
ditional increase (5- to 10-fold) closely correlated 
with postoperative intraabdominal infectious com-
plications which required reintervention. In those 
patients (n = 7) sepsis was clinically diagnosed be-
tween the third and sixth postoperative day. Pa-
tients with transient postoperative septic episodes 
showed a gradual normalization of elevated elas-
tase plasma levels within the first 3 - 4 days after 
surgery. In another study monitoring the early in-
flammatory response in 27 peritonitis patients, 
the authors emphasized the significant predictive 
value of elevated elastase plasma levels at the time 
of emergency laparotomy for the later outcome 
(survival/death) of the patients (Schöffel et al. 
1989b). 
In addition to measurements of the complexed 
elastase in plasma of adults, serial quantifications 
of this granulocytic proteinase in 306 neonates, car-
ried out by Speer and Tegtmeyer (1989), have prov-
en that this inflammatory mediator is both a highly 
sensitive and rapidly responsive indicator of 
neonatal septicemia and a helpful tool in monitor-
ing the course of the disease. When patients with 
neonatal septicemia were differentiated from those 
with other neonatal disorders, elevated complexed 
elastase levels showed a sensitivity of 95% and 
specificity of 8 1 % for the septic entity. Similar 
results were published by Tsaka and Herkner (1990) 
on 135 newborn infants. 
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Plasma Levels of Polymorphonuclear 
Granulocyte Elastase-Induced Split Products 
of Vital Proteins as Indicators of Unspecific 
Proteolysis in the Circulation 
Just recently we were able to verify the destructive 
proteolytic potency of P M N elastase in a still ongo-
ing prospective study (clinically directed by Dr. In-
thorn, Department of Surgery Großhadern, Univer-
sity of Munich) of septic patients. To be enrolled in 
this investigation, patients had to fulfill all four pre-
viously defined septic criteria (septic focus and/or 
positive blood culture; body temperature >38 .5°C; 
leukocytes >15000/uJ or <5000/uJ; platelets 
< 100000/jal or drop in platelets >20% within 
24 h ensuring a severe inflammatory situation. In 
patients with lethal outcome, the generation of the 
elastase-induced fibrinogen split product "fibrino-
elastase peptide (FEP)" (Gippner-Steppert 1991; see 
also the chapter by Jochum et al., pp 46-60) in the 
circulation was well correlated to high plasma levels 
of P M N elastase (Fig. 4). Moreover, the unspecific 
proteolytic degradation of AT I I I , which is also 
susceptible to P M N elastase cleavage (Jochum et 
al. 1981; Jordan et al. 1989), could be pointed out 
by an indirect method comparing the amount of 
AT I I I antigen with its inhibitory activity (Fig. 5). 
In patients suffering from eventually lethal sepsis 
AT I I I was not only considerably consumed (to 
about 50% of normal) throughout the whole sepsis 
period, but the clearly lower inhibitory activity (be-
tween 20% and 40%) also indicated that part of 
the antigen level may be due either to inactive com-
plexes of the inhibitor with clotting enzymes or to 
proteolytically degraded molecules. Since the latter 
have an only slightly lower molecular weight and 
nearly the same half-life as the intact molecules 
(Jordan et al. 1989), they cannot be distinguished 
from the native AT I I I i f quantified by radial im-
munodiffusion. In our patients, however, we could 
definitely rule out the possibility that AT III-pro-
teinase complexes contribute to a significant degree 
of the higher antigen levels in comparison to the in-
hibitory activity. Due to their very short half-life of 
only a few minutes, concentrations of AT I I I -
thrombin complexes made up at most only 0.01% 
of the overall AT I I I amount. Thus, elastase-inac-
tivated AT I I I molecules should be present with 
high probability in the pathological situation of 
severe sepsis. This assumption is further supported 
by results of Jordan et al. (1989) which demonstrat-
ed that even catalytic amounts of heparin react 
with elastase in a way considerably accelerating the 
rate of AT I I I inactivation by this enzyme. Since 
heparin exists not only as a minor component on 
vascular endothelial cells but is also used as a thera-
peutic drug in our patients, the positive regulation 
of hemostasis by heparin may be clearly counter-
acted by the adverse effect on AT I I I in case of a 
high release of elastase from P M N granulocytes 
adhering to the endothelial layer of the blood vessel 
walls. Moreover, as shown just recently by Fromm-
herz et al. (1991), inhibition of elastase by ^ - p r o -
teinase inhibitor (ajPI) is significantly retarded in 
the presence of heparin, which would further allow 
proteolytic degradation of susceptible plasma pro-
teins. 
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Fig. 4. Plasma levels of PMN 
elastase (in complex with ar 
proteinase inhibitor) and fibrino-
elastase-peptide (FEP) in a patient 
with lethal outcome 2 days after di-
agnosis of sepsis due to bifurcation 
malacia of the trachea 
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Fig. 5. Comparison of antithrom-
bin I I I (AT III) immune reactive 
levels (immun.) and inhibitory ac-
tivity (act.) in plasma samples of a 
patient with lethal sepsis 
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Polymorphonuclear Granulocyte Elastase 
and Cathepsin B in Peritonitis Exudates 
in Relation to the Local Degradation 
of Vital Proteins 
Diffuse peritonitis is often the source of a systemic 
spreading of local infectious complications even-
tually leading to sepsis and MOF. In a previous 
work we were able to demonstrate that the impair-
ment of opsonization in the peritoneal cavity 
allows the survival of huge numbers of bacteria, 
despite the presence of intact phagocytes (Billing et 
al. 1988 a, b, 1989). Since the proteolytic breakdown 
of the main opsonins IgG and complement factor 
C3 in peritonitis exudates correlated well with the 
extracellularly released lysosomal proteinases, elas-
tase and cathepsin B, in the local body fluids, we 
assumed that these enzymes are the principal cause 
of the deficiency in opsonic capacity (Fig. 6). To 
test this hypothesis, isolated IgG was incubated in 
vitro either with P M N elastase and cathepsins B / L 
or (in its isothiocyanate-labeled form = FITC-IgG) 
with a cell-free, purulent peritonitis exudate (kindly 
supplied by Dr. Billing, Department of Surgery 
Großhadern, University of Munich). The proteo-
lytic degradation was followed by gel chromatogra-
phy of the split products (Fig. 7) which exhibited a 
similar type of IgG cleavage pattern under all con-
ditions (Machleidt et al. 1993; Billing et al. 1991). 
Using the specific inhibitor E-64 we were able to 
demonstrate that part of the in vitro IgG cleavage 
by peritonitis exudates was due to cysteine pro-
teinases such as cathepsin B or L . Yet, the major 
portion of the proteolytic activity was abolished by 
Fig. 6. Opsonic capacity (determined by 
chemiluminescence assay), cathepsin B 
activity, and PMN elastase (in complex 
with a,-proteinase inhibitor) in peritonitis 
exudates (n = 28) 
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Fig. 7. Limited proteolysis of isolated human im-
munoglobulin G (IgG) and fluorescein isothiocyanate la-
belled IgG (FITC-IgG) by isolated lysosomal proteinases 
(PMN elastase, cathepsins B, L) and peritonitis exudate, 
respectively. IgG and IgG fragments were separated by 
fast gel chromatography on a Superose 12 FPLC column. 
A, intact IgG; B, (Fab)2 fragments; C, Fc and/or Fab 
fragments; D, low molecular mass buffer artifact present 
in all samples. E-64, a specific inhibitor of the cysteine 
proteinases cathepsin B and L which suppresses the 
cathepsin-related proteolytic activity in the exudate 
addition of a {PI substantiating proteolytic elastase 
activity despite the presence of a 40-fold molar 
surplus of a t P I antigen in peritonitis exudates. 
With resorufin-labeled casein as a substrate, high 
levels of proteolytic activity were found preferably 
in exudates with low opsonic capacity (Fig. 8). 
These findings closely resembled the data obtained 
from BALF samples in trauma patients (see the 
chapter by Jochum et al., pp 46-60). In addition to 
the in vivo and in vitro degradation of IgG and C3, 
we have successfully proven the in vivo generation 
of FEP in peritonitis exudates of 21 patients. As 
depicted in Fig. 9, high levels of complexed P M N 
elastase coincided with highly elevated FEP in the 
specimen drawn before surgical treatment of the 
abdomen of a patient with severe peritonitis. After 
rinsing the peritoneal cavity with 101 of Ringer's 
lactate solution both parameters decreased nearly 
to zero. Yet, as can be seen from the abdominal 
drainage fluids collected between 0 - 1 h, l - 2 h , 
and 2 - 8 h after operation, the release of P M N 
elastase started again, inducing also the production 
of FEP (Fig. 9). These observations may be taken 
as an indication of a still ongoing inflammatory 
reaction in this patient. 
Conclusions 
Summarizing the data obtained in our clinical 
studies and those of others on patients suffering 
from severe postoperative or posttraumatic infec-
tions, it could be clearly shown that the release of 
phagocyte proteinases, P M N elastase and cathepsin 
B, beyond normal values evoked by the physiological 
turnover of the phagocytes correlated well with the 
activation of proteolytic clotting enzymes, the con-
sumption of proteinase inhibitors, and the onset and 
severity of the acute inflammatory reaction. 
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Fig. 8. Opsonic capacity (°Io of the value found 
with normal serum) and proteolytic activity 
(measured with resorufin-casein as substrate) 
of peritonitis exudates (n = 28) 
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Fig. 9. PMN elastase (in complex 
with a,-proteinase inhibitor) and 
fibrino-elastase peptide (FEP) in 
exudate samples taken from a 
peritonitis patient before (preL) and 
immediately after (postL) lavage of 
the abdomen with Ringer's lactate 
solution and in drainage fluid col-
lected between 0-1 h, l - 2 h , and 
2-8 h after lavage 
Moreover, the studies showed without doubt 
that, in patients who have incurred severe infection 
followed major surgery or trauma, the underlying 
cellular and humoral biochemical events are quite 
similar regardless of the etiology of the insult. The 
clinical outcome seems to be only due to the 
magnitude of the inflammatory response, which is 
of course highest when trauma is superimposed by 
infection (Waydhas et al. 1992). 
As outlined in the chapter by Jochum et al. 
(pp 46-60), the role of P M N elastase as an inflam-
matory effector seems to be well established. In 
contrast, the role of the cysteine proteinase cathep-
sin B is less clear. Considering the relatively poor 
proteolytic action of cathepsin B on vital proteins 
in vitro, the destructive potential of cysteine pro-
teinases may be mainly due to cathepsin L which is 
likely to be released simultaneously with cathepsin 
B. 
Furthermore, it turned out that discharge of 
lysosomal phagocyte proteinases and the activation 
of proteolytic blood cascade enzymes in sepsis and 
in trauma effected an excessive local (ßiPI) and 
systemic (AT I I I ) consumption of proteinase in-
hibitors. Since these events seem to be the most crit-
ical cause allowing proteolysis-induced (multiple) 
organ failure, supplementation of the body's in-
hibitor potential by exogenous proteinase inhibitors 
against elastase and thrombin should be a highly 
promising approach in treating patients at high risk 
for septic MOF. 
Proteinase Inhibition as a Convenient 
Therapeutic Approach in Septic Multiple 
Organ Failure 
I f a putative causal mediator in acute inflammation 
such as septic MOF is, in fact, relevant, the use of 
specific mediator antagonists as therapeutic tools 
should prevent, or at least reduce to some extent the 
severe signs of inflammation, in accordance with 
Koch-Dale's criterion 4 as indicated by Neugebauer 
and Lorenz (1988). Since P M N elastase turned out 
to play a particularly important role in shock-asso-
ciated organ and hemostasis dysfunctions, we and 
others envisaged the therapeutic use of elastase in-
hibitors as the most promising approach to in-
terfere with proteolysis-induced pathomechanisms 
in acute inflammation (Jochum and Fritz 1990; 
Fritz et al. 1992; Braun and Schnebli 1986). 
Moreover, the excessive consumption of AT I I I dur-
ing severe inflammatory reactions, which enables 
unrestricted hemostatic proteinase activity further 
intensifying the overall pathological proteolysis, 
should be compensated for by the exogenous ad-
ministration of potent thrombin inhibitors (Vinaz-
zer 1987; Markwardt 1991; Bichler and Fritz 1991). 
Before administering such drugs to humans, 
especially drugs of nonhuman origin generated by 
gene technology or chemical synthesis, safety and 
efficacy has first to be demonstrated in convenient 
animal models. Thus, progress in sepsis research 
continues to depend upon studies using clinically 
relevant animal models which fulfill commonly ac-
cepted criteria of the sepsis syndrome. 
The working definition of the sepsis syndrome, 
applicable to both human and laboratory studies, 
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comprises a constellation of clinical and laboratory 
findings indicative of a generalized inflammatory 
response leading to acute organ dysfunctions often, 
but not invariably, associated with the presence of 
serious bacterial, fungal, or viral infection. Fur-
thermore, the septic shock phase is characterized by 
circulatory decompensation (i.e., hypotension) due 
to an exacerbation of the septic syndrome. 
Inhibitors of Polymorphonuclear Granulocyte 
Elastase or Thrombin in Experimental 
Septic/Endotoxin Shock 
Choice of a Convenient Animal Model 
To achieve a clinic-like situation in an experimental 
setting, a variety of different approaches have been 
used (extensively reviewed by Fink and Heard 
1990). Of those, i.v. infusions of viable bacteria or 
simply endotoxins (the main toxic cell wall consti-
tuents of gram-negative bacteria) are the most com-
mon. Although there are considerable doubts 
about the absolute clinical relevance of these ap-
proaches (e.g., because of differences in the hemo-
dynamic responses depending on the amount of the 
deleterious agent and the administration period), 
experimental bacteremia or endotoxinemia may 
nonetheless provide a reasonable paradigm for sep-
sis in humans, given the proviso that the animal 
model chosen adequately replicates those features 
of the clinical syndrome which should be explored 
in the experiment (e.g., release of phagocyte pro-
teinases in relation to organ dysfunctions). 
With respect to the relevant animal species 
selected in the different laboratory models of sepsis 
and septic shock, nonhuman primates and pigs 
have proven to be invaluable in the exploration of 
the underlying pathobiochemical mechanisms, 
because of the obvious similarities of these animals 
to humans concerning physiology and biochemical 
reactions. Thus Egbring and Havemann (1978) 
reported that a bolus infusion of 50 |ig Staphylo-
coccus abortus equi endotoxin/kg body weight 
in a green monkey induced not only the release 
of P M N elastase (demonstrated semiquantitative-
ly by one-dimensional Immunoelectrophoresis) 
within 20-300 min after the endotoxin injection, 
but also a concomitant decrease in activity of 
several coagulation factors, quite similar to find-
ings in septic patients (Egbring et al. 1986; Seitz 
et al. 1987; Egbring and Havemann 1978). Due 
to the antigenic identity of many plasma and 
cellular proteins, the application of a modified 
version of the ELISA test system for human 
P M N elastase also allows the exact quantification 
of the granulocyte proteinase in plasma of ba-
boons. As shown recently by Redl et al. (1991) 
using this test system, continuous i.v. administra-
tion of live Escherichia coli over 8 h in 7 baboons 
evoked a massive release of P M N elastase within 
1 h after starting the experiment up to the end of 
the observation period. Although normal plasma 
levels of extracellularly discharged P M N elastase in 
baboons reached only one-third that of humans, 
the 20- to 30-fold increase in septic animals was 
highly comparable to the situation in septic pa-
tients. 
Though the baboon model provides the most 
human-like situation in an experimental setting, 
pigs are normally preferred as experimental ani-
mals because of ethical and financial restrictions in 
many laboratories. Yet, in contrast to granulocytes 
of humans and nonhuman primates, porcine 
PMNs contain both proteolytic and inhibitory ac-
tivities. As shown by Geiger and colleagues (see 
review by Geiger et al. 1988) the main inhibitory ac-
tivity against lysosomal neutral serine proteinases 
such as elastase is a cytosolic serine proteinase in-
hibitor (SERPIN)-like protein called leukocyte 
neutral proteinase inhibitor (LNPI). This inhibitor 
is released simultaneously with elastase due to 
stimulation or disintegration of the P M N cells and 
inhibits effectively the elastolytic enzyme outside 
of the granulocytes. Thus, using a specifically 
developed ELISA test system, quantification of the 
elastase-LNPI complex in porcine plasma turned 
out to be a reliable measure of the extracellularly 
discharged P M N constituents (Geiger et al. 1988). 
Mean plasma levels of this complex in healthy pigs 
reached 16±11 ng/ml. In a preliminary study of 8 
septic pigs, up to 25-fold higher levels were ob-
served during the development of septicemia in-
duced by a 2 h infusion of live E. coli (Geiger et al. 
1988). Maximal values were measured about 10 h 
after the end of the bacterial administration. These 
results could be clearly confirmed in a second ran-
domized trial, in which the release of the porcine 
P M N constituents were highly correlated with the 
occurrence of hypotension and hypoproteinemia 
due to infusion of viable bacteria (Siebeck et al. 
1989 a). In another prospectively controlled, ran-
domized, short-term study performed by our re-
search group (Hoffmann et al. 1990), a similar sig-
nificant increase of P M N elastase in complex with 
L N P I to above normal was noticed concomitant 
with the development of organ dysfunctions in 18 
pigs receiving a continuous infusion of S. abortus 
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equi endotoxin over the whole observation period 
of 6 h. No such changes occurred in sham-treated 
control animals. 
In addition to serving as a model for P M N 
elastase release in septic/endotoxic situations, pigs 
are the only animal species in which an ex-
tracellular discharge of the monocyte/macrophage-
derived cysteine proteinase cathepsin B above nor-
mal after endotoxin infusion has been reliably dem-
onstrated (Assfalg-Machleidt et al. 1990; Siebeck et 
al. 1991). Starting from a normal level of about 
200 mU/1 (corresponding to 4-fold that of normal 
values in healthy humans) i.v. infusion of S. 
abortus equi endotoxin for 6 h in 19 pigs evoked a 
steady increase of cathepsin B in plasma up to 3.5-
fold that of normal at the end of the 6 h observa-
tion period (Assfalg-Machleidt et al. 1990). Con-
comitant with this increase a significant decrease in 
arterial blood pressure occurred, indicating a severe 
septic shock state. In contrast, sham-treated control 
animals (n = 7) did not show any remarkable 
pathophysiological changes. Similar results could 
be demonstrated in another randomized trial with 
11 pigs also receiving a 6 h continuous infusion of 
S. abortus equi endotoxin (Siebeck et al. 1991). In 
this study the endotoxin-induced rise of cathepsin 
B was partially reduced in 13 animals treated with 
the platelet activating factor (PAF) receptor an-
tagonist WEB 2086 compared with the 11 septic 
untreated controls, indicating that cathepsin B 
release may have been mediated to some extent by 
PAF in the experimental setting. 
Results of Inhibitor Therapy 
in Septic/Endotoxemic Pigs 
In a preliminary controlled study on E. coli sepsis 
in young pigs, the prophylactic administration of 
the relatively specific recombinant elastase in-
hibitor eglin c (originally isolated from the leech 
Hirudo medicinalis) caused a significant reduction 
in the consumption of AT I I I and other plasma 
proteins as well as in the formation of interstitial 
pulmonary edema (Jochum et al. 1987). As assess-
ed by measurement of arterial blood pressure and 
total protein concentration in plasma, Siebeck et al. 
(1989 a, b) demonstrated in a more extended study 
that eglin c can also reduce hypotension and the 
overall capillary leakage induced by the infusion of 
live E. coli into pigs. In this study, significantly 
lower concentrations of the elastase-LNPI complex 
in plasma were measured under eglin c administra-
tion, presumably indicating extreme rapid competi-
tion of the exogenous elastase inhibitor with the 
granulocyte-derived serine proteinase antagonist 
L N P I (Siebeck et al. 1989 a). Such a rapid complex-
ation by eglin c seems to prevent proteolytic activity 
of released elastase more effectively than by the en-
dogenous inhibitor. 
Moreover, in a further controlled investigation, 
Siebeck et al. (1989c) and Hoffmann et al. (1990) 
could show that, besides eglin c, the thrombin-
specific inhibitor hirudin - another recombinant 
inhibitor also formerly isolated from the medical 
leech - significantly improved endotoxin shock 
syndromes in minipigs. Fibrinogen consumption, 
formation of fibrin monomers, the occurrence of 
pulmonary vasoconstriction, and the release of 
P M N constituents were clearly lower in endotox-
emic animals treated prophylactically with hirudin 
than in those without continuous intravenous in-
hibitor infusion. Since hirudin does not interfere 
with P M N elastase inhibition by endogenous in-
hibitors, the conclusion can be drawn that the ac-
tivation of clotting enzymes, which are known as 
potent, direct or indirect stimulators of P M N cells 
(Wachtfogel et al. 1983, 1985; Lo et al. 1988), was 
effectively reduced by inhibition of thrombin, thus 
also lowering the stimulation of P M N granulo-
cytes. 
Interestingly, supplementation of a purified AT 
III-heparin complex in another randomized por-
cine endotoxin shock model had only a slight, in-
significant, positive effect on endotoxin-induced 
mortality and oxygen saturation in arterial blood 
(as an indication of pulmonary function), although 
the consumption of fibrinogen and the formation 
of soluble fibrin monomers were clearly prevented 
in the drug-treated animals (Spannagl et al. 1991). 
Furthermore, prothrombin consumption was simi-
lar in the treatment and placebo groups suggesting 
that local thrombin generation via factor Xa and 
binding of both enzymes to endothelial cell mem-
brane receptors may protect them from inhibition 
by the AT III-heparin complex. However, the 
amount of the AT III-heparin complex may not 
have been sufficient to inhibit activation of contact 
phase enzymes (plasma kallikrein, factor X I I a) 
which are supposed to be potent stimulators of 
P M N granulocytes (Wachtfogel et al. 1983, 1985) as 
mentioned before. Therefore, the inflammatory 
process might have been maintained primarily via 
the release of phagocyte proteinases and reactive 
oxygen metabolites. Moreover, since after an initial 
rise (up to about 130%) the AT I I I activity decreas-
ed during further drug administration while the an-
tigen level still increased, the heparin in the com-
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plex may have facilitated inactivation of AT I I I by 
released PMN elastase (Jordan et al. 1989), thereby 
lowering the inhibitory capacity under an otherwise 
presumably effective threshold level. 
The requirement of high levels of AT I I I in-
hibitory activity in the circulation is also confirmed 
by results of Emerson et al. (1989) concerning the 
efficacy of AT I I I supplementation in several 
animal models (rat, sheep, baboon) of fulminant E. 
coli endotoxemia or bacteremia. Only very high 
doses (up to 3-fold that of normal) and prophylac-
tic administration of AT I I I prevented organ 
damage and increased permanent survival in the 
experimental animals. Interestingly, the combined 
application of AT I I I and ajPI showed a signifi-
cant synergistic improvement of pulmonary func-
tion compared to single drug treatment in the en-
dotoxemic sheep model. This indicates again that a 
complex interaction of lysosomal and humoral 
blood cascade proteinases contributes to the 
perpetuation of a septic-like inflammation. 
Systemic Supplementation of Antithrombin III 
in Clinical Sepsis 
Beside the therapeutic animal experiments, prelimi-
nary clinical studies (reviewed by Vinnazer 1987, 
Seitz et al. 1989, Schwartz et al. 1989) have also 
proven the postulated positive effects of thrombin 
inhibition on the hemostatic system by AT I I I sup-
plementation in severely i l l patients. Yet, a statisti-
cally significant reduction in MOF or lethality 
compared to untreated patients could be verified in 
only a few trials. In these studies just normal 
plasma levels of AT I I I were achieved by the 
therapeutic regimen, infusing purified human AT 
I I I concentrates. Thus, we draw the conclusion that 
only AT I I I levels well above the normal plasma 
range may be able to interfere with phagocyte-
derived inflammatory reactions, thereby improving 
not only disseminated intravascular coagulation 
but also organ dysfunctions in clinical sepsis. In ad-
dition, this assumption is especially supported by 
our animal experiments (Spannagl et al. 1991) and 
those of Emerson et al. (1989). 
We, therefore, conducted a prospective random-
ized study (clinically directed by Dr. Inthorn, De-
partment of Surgery Großhadern) of septic patients 
with the aim to increase the AT I I I inhibitory activi-
ty at least above 120% that of normal. To achieve 
this, AT I I I concentrates were i.v. infused twice daily 
over 21 days according to a modified regimen origi-
nally described by Blauhut et al. (1985). Blood 
samples were taken twice daily throughout the 
whole observation period. Preliminary data and a 
detailed outline of the performance of the still ongo-
ing trial have been published by Jochum et al. 
(1991). Here, only the most important results will be 
presented. Up to now, 30 patients, all fulfilling the 
above mentioned septic criteria, could be enrolled in 
the control (n = 15) and therapy groups (n = 15). 
With our administration scheme the AT I I I ac-
tivity in the treatment group was elevated to mean 
plasma levels slightly below 120% during the first 
9 days followed by an increase above 120% 
thereafter, whereas in the control group levels be-
tween 60% (early phase) and 80% (later phase) 
were measurable. Although all AT Ill-treated pa-
tients received nearly the same amount of the in-
hibitor concentrate (between 8000 and 4000 units 
per day), those individuals who survived the septic 
event showed clearly higher AT I I I levels (up to a 
mean of 135% during the first 5 days after sepsis 
diagnosis) than patients who died despite AT I I I 
supplementation (mean AT I I I activity between 
100% and 115% in the early septic phase) (Fig. 10). 
Thus, immediate AT I I I substitution in sufficiently 
high amounts after early diagnosis of a septic 
episode appears to be of great importance in im-
proving the survival of the patients. 
Probably due to a too late onset of inhibition 
therapy along with administration of still insuffi-
ciently high AT I I I doses in some of our patients, 
the overall mortality could be reduced only from 
87% in the control group to 60% in the AT I l l -
treated collective. This diminution in lethality was 
statistically not significant, yet a clear improvement 
of organ functions - especially of lung, liver, and 
kidney - in the treated patients and a further 
deterioration in the control group became evident. 
Mean plasma levels of complexed elastase were 
elevated up to 6-fold that of normal upon admis-
sion and decreased gradually to about 3-fold in 
both groups until the end of the observation 
period. Although there were no statistically signifi-
cant differences, a slight trend to lower plasma 
elastase levels appeared in the AT I I I group. In con-
trast, an obvious reduction of complexed elastase in 
plasma due to AT I I I supplementation was demon-
strated by Seitz et al. (1989). 
In our study, plasma prekallikrein and pro-
thrombin levels were highly reduced, up to 30% 
and 50%, respectively, upon sepsis diagnosis and 
showed a more or less pronounced change to higher 
values (40% and 80% that of normal) later on 
without distinct differences in the placebo and 
treatment groups (Fig. 11). Interestingly, however, 
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Fig. 10. Mean values of antithrombin 
I I I inhibitory activity (measured as % 
of NP = Normal Plasma in plasma of 
septic patients treated with AT I I I ; 
survivors (n = 6); nonsurvivors (n = 9) 
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Fig. 11. Mean values of prekalli-
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prekallikrein levels rose steadily up to 50% in AT 
Ill-treated survivors, whereas in the nonsurvivors a 
further transient decrease up to 20% occurred 
(Fig. 12). A n analogous behavior was observed for 
prothrombin, which reached 80% that of normal 
10 days after onset of sepsis in the AT Ill-treated 
survivors, while in the moribund patients plasma 
prothrombin levels as low as 60% were measured at 
that time. Thus, the rise in AT I I I inhibitory activi-
ty to nearly 140% in the early septic phase may 
have been beneficial enough to preserve clotting 
proenzymes from excessive activation throughout a 
septic period. Nevertheless, it became obvious from 
our findings that a convincing improvement of the 
overall septic state deserves an even higher and 
earlier substitution of AT I I I than that used in this 
study. 
Local Administration of Serum in Peritonitis 
In diffuse peritonitis, phagocytosis of bacteria is 
impaired by the drastically diminished opsonic 
capacity of the exudate due to proteolytic (and ox-
idative?) inactivation of the major opsonins IgG 
and complement factor C3 (see above). Intraab-
dominal administration of serum, containing both 
high amounts of intact opsonins and a broad spec-
trum of proteinase inhibitors, should improve the 
situation. In a pilot study Billing et al. (1991) ob-
served an increased opsonic capacity when 300 ml 
of blood bank serum was instilled into the ab-
dominal cavity at the end of the operation pro-
cedure and lavage of the whole abdomen with 101 
of Ringer's lactate solution. Just recently, these 
preliminary results were confirmed in a controlled 
study involving 15 patients receiving serum after 
lavage and 15 controls lavaged without subsequent 
serum application (Billing 1992). Exudate samples 
were drawn before and after abdominal lavage and 
from the postoperative drainage fluid collected 
between 0 - 1 h, l - 2 h , and 2 - 8 h after opera-
tion. After rinsing the abdominal cavity with 
Ringer's lactate solution, the reduced opsonic 
capacity of the exudate increased only slightly in 
the control group, whereas in the therapy group 
with subsequent intraabdominal administration of 
300 ml serum a highly significant improvement of 
opsonic capacity was observed over 8 h (Fig. 13). 
The higher opsonic capacity of the exudate deter-
mined in the ex vivo samples correlated with 
microbiological data indicating an enhanced elimi-
nation of bacteria and an improved clinical out-
come of the patients in the therapy group (Billing 
1992). 
In addition, we found a marked difference be-
tween ajPI antigen and inhibitory activity (mea-
sured against trypsin) in the primary exudates of 
both the serum and the control groups indicating 
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that part of the inhibitor was inactive due to oxida-
tion and/or proteolytic cleavage (Fig. 14). This dif-
ference was abolished by rinsing the abdomen even 
without serum administration, but significantly 
higher postoperative a r P I levels were reached and 
sustained in the serum group. After operation and 
abdominal lavage the proteolytic activity of the 
drainage fluid measured with resorufin-casein as 
substrate was greatly reduced but not completely 
abolished (Fig. 15). Serum administration seemed 
to slow down the reincrease of proteolytic activity, 
but the differences compared to the control group 
were not statistically significant. Thus, proteinase 
inhibition by the given amount of serum may not 
be sufficient, and additional supplementation of 
proteinase inhibitors should be envisaged to im-
prove the therapeutic effect. 
60 
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Fig. 13. Effect of intraabdominal serum administration 
on the opsonic capacity of peritonitis exudates (in % of 
the value obtained with normal serum). Samples were 
taken before (preL), immediately after (postL) lavage of 
the abdomen with Ringer's lactate solution and 
postoperatively from drainage fluids collected between 
0 - 1 h, 1 - 2 h, and 2-8 h after lavage. Values are given 
as mean (±SEM) for control (n = 15, dotted line) and 
serum-treated (n = 15, solid line) patients; ** differences 
statistically significant (p<0.01) 
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Fig. 14. Effect of intraabdominal serum administration 
on a,-proteinase inhibitor (a/PI) antigen concentration 
and inhibitory activity in peritonitis exudates. Values are 
given as mean (±SEM) for control (n = 15, dotted line) 
and serum-treated (n = 14, solid line) patients. For sam-
ple collection see Fig. 13; * statistically significant 
(/?<0.05) difference between a,PI antigen concentra-
tions of serum group and control group 
Conclusions 
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Fig. 15. Effect of intraabdominal serum administration 
on the proteolytic activity in peritonitis exudates; mea-
sured with the substrate resorufin-casein. For further 
details see Figs. 13 and 14 
The data derived from the therapeutic experimental 
and clinical studies on acute inflammation un-
equivocally indicate that proteolytic pathomecha-
nisms due to phagocyte and hemostasis proteinases 
play an important role in the onset and perpetua-
tion of inflammatory processes such as sepsis-in-
duced multiple organ dysfunctions. Therefore, 
plasma levels of regulatory elastase and thrombin 
inhibitors have to be elevated by a suitable sup-
plementation and kept well above the normal in-
hibitory activity in healthy people to achieve a sig-
nificant improvement of the clinical situation in 
severely i l l patients. 
Despite the fact that the leech-derived elastase 
and thrombin inhibitors eglin c and hirudin have 
shown a high efficacy in animal experiments, their 
clinical use has to be considered with caution, 
especially concerning the putative antigenicity of 
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nonhuman proteins in long-term studies. Thus, a 
therapeutic approach with isolated, purified, 
human plasma inhibitor preparations (o^PI, AT 
I I I ) is the only clinical choice at present. 
The natural sources for the isolation of pro-
teinase inhibitors from human material are very 
limited. Thus, molecular modeling to design highly 
effective inhibitory proteins on the basis of human 
inhibitor molecules and their production by recom-
binant DNA technology is the most promising ap-
proach to get the quantities necessary for pro-
teinase inhibition therapy in the future (Fritz et al. 
1992). 
Summary 
Several years ago, Neugebauer et al. (1987) outlined 
in detail more than 100 different mediators that 
were causally related to acute inflammation and 
circulatory shock. Despite or probably because of 
the fact that none of these factors have yet been un-
equivocally shown to be of ultimate relevance, there 
is still a growing number of new mediators which 
have been proposed as playing the central role in an 
acute inflammatory process such as multiple trau-
ma and sepsis. To establish, however, a cause-effect 
relationship for a single mediator of shock, the 
classical criteria of Koch-Dale for being a causal 
chemical factor in a pathological reaction should 
be considered in a modified version using meta-
analysis and models of decision trees as suggested 
by Neugebauer et al. (1987) and Neugebauer and 
Lorenz (1988). 
Since not a single factor but rather a mixture of 
causal inflammatory mediators act in concert to 
evoke a sepsis-like syndrome following severe trau-
ma (see the chapter by Jochum et al., pp 46-60), 
major surgery, or infection, we have been especially 
interested in the extent that proteolytic pathomecha-
nisms may participate in the initiation and perpetua-
tion of these acute inflammatory processes. Although 
we did not use meta-analysis procedure and models 
of decision trees in detail, a more or less narrative 
review of our research and that of other authors 
with respect to the topic of interest revealed a promi-
nent role for proteinases in acute inflammation. 
This statement is based on the following evidence: 
1. Release of the lysosomal phagocyte proteinases, 
PMN elastase and monocyte/macrophage-de-
rived cathepsin B, and activation of proteolytic 
blood cascade enzymes in proportion to the 
severity of trauma-, surgery-, and/or bacteria-in-
duced inflammation could be clearly verified in 
a variety of clinical studies. Moreover, the 
amounts of the extracellularly discharged phago-
cyte proteinases in plasma at an early stage of the 
disease were highly predictive for forthcoming 
organ failure and ultimate outcome. 
2. The consumption of proteinase inhibitors («iPI, 
AT I I I ) and other plasma proteins susceptible to 
proteolytic degradation coincided with the occur-
rence of proteolytic activity, especially that of 
PMN elastase. 
3. Split products of functional proteins specifically 
generated by the phagocyte proteinases could be 
demonstrated in local and systemic human body 
fluids correlating with the extracellular release of 
these enzymes. 
4. The therapeutic use of specific PMN elastase or 
thrombin inhibitors in experimental septic/en-
dotoxin shock or clinical sepsis, respectively, 
prevented or at least reduced to some extent 
severe signs of inflammation. 
Yet, despite these convincing data, ultimate assess-
ment of the relevance of proteolytic enzymes in 
shock states, notwithstanding the numerous other 
candidate mediators, requires application of the 
probabilistic model suggested by Neugebauer and 
Lorenz (1988), i.e. showing that the factor of interest 
is a necessary, sufficient, or contributory determi-
nant. 
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